Sanofi (SNYNF)

OTCMKTS · Delayed Price · Currency is USD
93.60
+0.62 (0.67%)
Feb 17, 2026, 3:48 PM EST
Market Cap111.71B -16.2%
Revenue (ttm)54.85B +5.5%
Net Income9.17B +40.5%
EPS7.52 +44.2%
Shares Outn/a
PE Ratio12.18
Forward PE9.39
Dividendn/a
Ex-Dividend Daten/a
Volume100,792
Average Volume73,425
Open93.76
Previous Close92.98
Day's Range93.60 - 93.76
52-Week Range90.05 - 122.03
Beta0.37
RSI46.78
Earnings DateJan 29, 2026

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange OTCMKTS
Ticker Symbol SNYNF
Full Company Profile

Financial Performance

In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.

Financial numbers in EUR Financial Statements

News

Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report

Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report

1 day ago - GlobeNewsWire

Sanofi, Teva Report Positive Phase 2b Results For Duvakitug

(RTTNews) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerative coliti...

1 day ago - Nasdaq

Sanofi announces leadership evolution in Specialty Care Business Unit

CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026.

1 day ago - PRNewsWire

Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) will hold an investor call and webcast today to highlight new Phase 2b maintenance data for Duvakitug. The investigational thera...

1 day ago - Nasdaq

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study. Positive Data Fr...

1 day ago - Benzinga

Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's

Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's

1 day ago - GuruFocus

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tole...

1 day ago - Benzinga

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease In the RELIEVE UCCD LTE phase 2b study, duvakitug sh...

1 day ago - Benzinga

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

1 day ago - GlobeNewsWire

Sanofi (SNY) Study Shows Significant Reduction in Infant RSV Hospitalizations

Sanofi (SNY) Study Shows Significant Reduction in Infant RSV Hospitalizations

1 day ago - GuruFocus

Sanofi expands Hyd GCC, to host around 5k workers

Hyderabad: In a move that bolsters Hyderabad's rapidly growing stature as a pharma global capability centre, Sanofi Healthcare India has expanded its .

2 days ago - The Times of India

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

French drugmaker Sanofi said on Monday it will expand its global capability centre (GCC) in the southern Indian city of Hyderabad, and increase its workforce to more than 4,500 employees.

2 days ago - Reuters

Sanofi: Beyfortus Study Shows Benefit For Infants Beyond First RSV Season

(RTTNews) - Sanofi (SNY) said a universal respiratory syncytial virus immunization program using Beyfortus or nirsevimab was associated with a statistically significant reduction in RSV-related hospit...

2 days ago - Nasdaq

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV...

2 days ago - GlobeNewsWire

Sanofi (SNY) Appoints New CEO Amidst Stock Challenges

Sanofi (SNY) Appoints New CEO Amidst Stock Challenges

5 days ago - GuruFocus

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Sanofi SA (NASDAQ: SNY) shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline. On Thursday, the French drugmaker with ...

5 days ago - Benzinga

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Sanofi SA (NASDAQ: SNY) shares are down during Friday's premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.

5 days ago - Benzinga

Sanofi's new CEO needs to fix drug pipeline and navigate Trump

Sanofi's incoming CEO, 65-year-old Belén Garijo, faces a major task to win over investors, accelerate the French company's stalled drug development pipeline and navigate vaccine scepticism in the Unit...

5 days ago - Reuters

French vaccine maker Sanofi ousts CEO Paul Hudson with Merck boss to take over

French drugmaker Sanofi ousted CEO Paul Hudson on Thursday, ending a six-year tenure marked by a stalled drive to replace blockbuster drugs going off patent and rising pressure from US anti-vaccine po...

5 days ago - Independent Ireland

Sanofi SA (SNY) Stock Price Down 3.43% on Feb 12

Sanofi SA (SNY) Stock Price Down 3.43% on Feb 12

6 days ago - GuruFocus

Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson

Sanofi stock skidded Thursday after the pharma giant's board ousted Paul Hudson as CEO, replacing him with Merck KGaA's Belen Garijo.

6 days ago - Investor's Business Daily

Sanofi Shares Fall After CEO Change

6 days ago - The Wall Street Journal